UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

 

Date of Report (Date of earliest reported): April 10, 2019

 

MANHATTAN SCIENTIFICS, INC.

(Exact name of registrant as specified in charter)

 

Delaware

 

000-28411

 

85-0460639

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

The Chrysler Building

405 Lexington Avenue, 26th Floor

New York, New York, 10174

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, including area code: (212) 541-2405

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 
 

 

Item 4.01 Change in Registrants Certifying Accountant

 

AMC Auditing, LLC. ("AMC"), the independent registered public accounting firm of Manhattan Scientifics, Inc. (the "Company"), announced effective February 1, 2019, that AMC was acquired by a new auditing firm, Prager Metis CPA’s LLC (“Prager”), and that all of the employees of AMC were joining Prager.

 

As a result, effective April 10, 2019, AMC resigned as the Company's independent registered public accounting firm. The Company's Board of Directors engaged Prager to serve as the Company's independent registered public accounting firm effective April 10, 2019.

 

The reports of AMC on the financial statements of the Company as of and for the fiscal years ended December 31, 2018, contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the report contained a paragraph stating there was substantial doubt about the Company's ability to continue as a going concern..

 

During the Company's fiscal years ended December 31, 2018 and the subsequent interim period from December 31, 2018 to the date of this report, and in connection with the audit of the Company's financial statements for such periods, there were no disagreements between the Company and AMC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of AMC, would have caused AMC to make reference to the subject matter of such disagreements in connection with its audit reports on the Company's financial statements.

 

During the Company's fiscal years ended December 31, 2018, and the subsequent interim period from December 31, 2018 to the date of this report, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.

 

During the Company's fiscal years ended December 31, 2018, and the subsequent interim period from December 31, 2018 to the date of this report, the Company did not consult with Prager regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.

 

The Company has provided AMC with a copy of the disclosures in this report and has requested that AMC furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not AMC agrees with the statements in this Item 4.01. A copy of this letter is filed as Exhibit 16.1 to this report.

 

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit

 

 

Number

 

Description

 

 

16.1

 

Letter to Securities and Exchange Commission from AMC Auditing, LLC dated April 12, 2019

 

 
2
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

MANHATTAN SCIENTIFICS, INC.

  

 

Date: April 12, 2019

By:

/s/ Emmanuel Tsoupanarias

 

New York, New York

Name:

Emmanuel Tsoupanarias

 

Title:

Chief Executive Officer

 

 
3

 

Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Manhattan Scientifics (PK) Charts.
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Manhattan Scientifics (PK) Charts.